Activity Overview
ACR Convergence 2025 On Demand features recorded sessions from the premier international rheumatology meeting that took place in Chicago, Illinois. See cutting-edge insights across basic and clinical science with flexible, self-paced access to plenaries and symposia.
Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.
Target Audience
Advanced practice nurses, counselors, dietitians, division directors, epidemiologists, fellows in training, health service researchers, nurses, occupational therapists, office managers/staff, pharmacists, practice administrators, primary care providers, physical therapists, physician associates, program directors, psychologists, researchers, residents, rheumatologists, rheumatology interprofessionals, social workers / community health workers, and students.
Learning Objectives
Upon completion of this activity, participants should be able to:
Assess their knowledge and competence in various rheumatic diseases and conditions
Support their skills in evaluating and diagnosing patients with rheumatic diseases
Discuss and collaborate on challenging cases with peers
Analyze emerging trends and technologies in rheumatology
Employ evidence-based approaches for managing rheumatic conditions
Identify new approaches and strategies for patient management
Interpret recent clinical trial and research findings
Apply new information from basic and clinical science to improve the care of people with rheumatologic illness
CE & MOC
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
Credit must be claimed by October 24, 2026, at 11:59 PM ET.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for diplomates to the diplomate number and date of birth provided when you claimed credit. Points are sent nightly to ACCME and then transferred to physician portals. Please allow at least 48 hours for points to display in the portal.
AMA Designation Statement
The American College of Rheumatology designates this Enduring Material for a maximum of 210.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 210.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MOC Recognition Statement: American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 210.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. ACR Convergence 2025 On Demand Financial Relationship Disclosures
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Overview
Designed for clinicians, trainees, and healthcare professionals, this session delves into the nuanced, often overlooked aspects of rheumatologic care with a particular focus in lupus, connective tissue disorders, and complex autoimmunity. Discover expert tips, diagnostic shortcuts, and therapeutic strategies that can transform clinical practice. From subtle clinical signs to evidence-based management pearls, this session offers a treasure trove of practical wisdom drawn from real-world experience and cutting-edge research.
Target Audience
Rheumatologists, rheumatology interprofessionals, physician assistants, primary care providers who care for patients with rheumatic disease, fellows-in-training, and residents.
Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss key diagnostic clues, hidden patterns, and apply expert insights ('pearls') to enhance the diagnosis and management of complex rheumatological conditions
Distinguish uncommon presentations for more accurate diagnosis and optimal treatment of rheumatic diseases
Explain useful rules and less well-known facts of rheumatic diseases, especially relevant to clinicians and trainees
CE & MOC Information
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
Credit must be claimed by December 11, 2028, at 11:59 PM ET.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
AMA Designation Statement
The American College of Rheumatology designates this Enduring Material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. ACR Convergence Replay 2025: Secrets and Pearls of Rheumatology Webinar Financial Relationship Disclosures
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Overview
The ACR Year in Review includes two expert-led videos. Always a highlight of Convergence, this session offers an overview of impactful literature published in the 12 months prior. Drs. England and Davidson, leaders in clinical and basic science research of rheumatic diseases, deliver a compelling overview of cutting-edge concepts in rheumatology.
Target Audience
Rheumatologists, physician assistants, fellows in training, rheumatology interprofessionals, and students.
Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.
Learning Objectives
Upon completion of this activity, participants should be able to:
Evaluate recent advancements in the treatment of pediatric and adult systemic lupus erythematosus to inform evidence-based clinical decisionHeading-making
Summarize recent advances in the classification, diagnosis, and treatment of vasculitis to enhance clinical decision-making and patient outcomes
Analyze the clinical and laboratory findings, diagnostic approach, and pathophysiology of macrophage activation syndrome to facilitate early recognition and intervention in rheumatologic settings
Integrate recent diagnostic criteria and emerging treatment strategies to improve the management of patients with gout
Recognize and classify common and atypical cutaneous manifestations associated with rheumatic diseases to support accurate diagnosis and timely referral or treatment
Differentiate true myositis from its clinical mimics using diagnostic criteria, imaging, and laboratory findings to avoid misdiagnosis and guide appropriate management
Apply key pharmacologic principles and clinical insights to optimize drug management strategies in patients with rheumatic diseases
Interpret clinical and imaging findings associated with inflammatory brain disease to enhance diagnostic accuracy and management strategies in rheumatologic practice
CE & MOC Information
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
Credit must be claimed by December 4, 2028, at 11:59 PM ET.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
AMA Designation Statement
The American College of Rheumatology designates this Enduring Material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Overview
The ACR Rheumatology Review Course consists of eight lectures spanning the scope of rheumatology. This full-day session, which took place during ACR Convergence 2025, is designed to provide a comprehensive update for practitioners.
Target Audience
Rheumatologists, physician assistants, fellows in training, rheumatology interprofessionals, and students.
Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.
Learning Objectives
Upon completion of this activity, participants should be able to:
Evaluate recent advancements in the treatment of pediatric and adult systemic lupus erythematosus to inform evidence-based clinical decisionHeading-making
Summarize recent advances in the classification, diagnosis, and treatment of vasculitis to enhance clinical decision-making and patient outcomes
Analyze the clinical and laboratory findings, diagnostic approach, and pathophysiology of macrophage activation syndrome to facilitate early recognition and intervention in rheumatologic settings
Integrate recent diagnostic criteria and emerging treatment strategies to improve the management of patients with gout
Recognize and classify common and atypical cutaneous manifestations associated with rheumatic diseases to support accurate diagnosis and timely referral or treatment
Differentiate true myositis from its clinical mimics using diagnostic criteria, imaging, and laboratory findings to avoid misdiagnosis and guide appropriate management
Apply key pharmacologic principles and clinical insights to optimize drug management strategies in patients with rheumatic diseases
Interpret clinical and imaging findings associated with inflammatory brain disease to enhance diagnostic accuracy and management strategies in rheumatologic practice
CE & MOC Information
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
Credit must be claimed by November 20, 2028, at 11:59 PM ET.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for diplomates to the diplomate number and date of birth provided when you claimed credit. Points are sent nightly to ACCME and then transferred to physician portals. Please allow at least 48 hours for points to display in the portal.
AMA Designation Statement
The American College of Rheumatology designates this Enduring Material for a maximum of 5.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MOC Recognition Statement: American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 5.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. Rheumatology Review Course 2025 Financial Relationship Disclosures
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.